Launch of PROCESSUS® Instrument Decontamination
Byotrol Plc
("Byotrol" or the "Company")
Launch of PROCESSUS® Instrument Decontamination System
Leading antimicrobial technology company Byotrol plc (AIM:BYOT) has today announced the launch of PROCESSUS®, a 360-degree instrument decontamination system, intended for the simple and effective reprocessing of instruments and specialist equipment, in both animal and human healthcare organisations.
PROCESSUS® is the third launch of Byotrol's next-generation surface disinfectant technology, which was first introduced in November 2022, under Byotrol's market-leading ANIGENE brand and subsequently launched under the CHEMGENE brand earlier this year.
Instrument decontamination refers to the process of making instruments and equipment safe for use. This can be achieved by removing, deactivating, or destroying contaminants, which can range from organic dirt and debris to harmful pathogens, like viruses, bacteria, and fungi. While the pathogenic threats to good patient care may differ slightly, the fundamental principles of effective instrument decontamination remain the same in both human and animal health environments.
The new PROCESSUS® brand debuts at the London Vet Show on the 16th November, where Byotrol will be demonstrating the ease-of-use and flexibility of the PROCESSUS® product range to animal health professionals from its key commercial partners in veterinary, welfare and rehoming charities, and zoos and wildlife organisations.
The PROCESSUS® Instrument Decontamination System incorporates enzymatic cleaners, which are designed to remove organic matter prior to disinfection, using a triple enzyme formulation which protects the integrity of instruments. Post-cleaning, PROCESSUS® Instrument Disinfectant kills bacteria, yeasts, fungi, and viruses, including multi-drug resistant pathogens as well as denaturing DNA / RNA.
Central to all Byotrol products, the PROCESSUS® Instrument Decontamination System is supported by rigorous testing to the latest European efficacy test methodology, specifically those required for instrument submersion. The formulation is compatible with a wide range of equipment including thermos-sensitive and fine lumened devices, nasal / fibre-optic scopes, diagnostic and orthopedic equipment, and surgical and endontic instruments.
David Traynor, Interim CEO of Byotrol states:
"The launch of Byotrol's new PROCESSUS® Instrument Decontamination System demonstrates another step forward in our plans to future-proof our portfolio for EU and UK BPR regulatory approvals. It is the third in a series of strategic portfolio updates, which strengthens our offering in both animal health and human health markets."
For detailed information about the forthcoming PROCESSUS® Instrument Decontamination range and supporting product documentation please visit our commercial website, www.byotrol.com and follow the company on LinkedIn.
For further information contact:
|
Byotrol Plc |
|
|
Dr Trevor Francis, Non- Executive Chairman |
+44 (0)1925 742 000 |
|
David Traynor, Interim Chief Executive Officer Chris Sedwell, Chief Financial Officer
|
investorrelations@byotrol.com |
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
+44 (0)20 7220 0500 |
|
Geoff Nash / George Dollemore - Corporate Finance |
|
|
Nigel Birks / Harriet Ward - ECM |
|
|
|
|
|
Flagstaff Strategic and Investor Communications |
+44 (0)20 7129 1474 |
|
Tim Thompson/Andrea Seymour/Fergus Mellon
|
|
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in animal health, human health, consumer products and facilities management sectors. Byotrol develops and commercialises innovative biocidal technologies and brands which provide targeted protection against harmful pathogens.
For more information about Byotrol plc please visit byotrolplc.com and follow the company on LinkedIn.
For information on Byotrol products and customers please visit byotrol.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 52 minutes ago Croda International
- 1 hour ago Diageo
- 1 hour ago IMI
- 2 hours ago Softcat
- 5 hours ago Tertiary Minerals